Vincerx Pharma Inc - VINC STOCK NEWS

Vincerx Pharma reported significant progress in its clinical studies and financial results for Q1 2021. The FDA cleared the IND for VIP152, enabling a Phase 1b trial for patients with relapsed/refractory chronic lymphocytic leukemia, set to begin in 2H 2021. The company also expects to initiate dosing for MYC-driven cancers in Q2 2021. Financially, Vincerx ended Q1 with $53.4 million in cash, down from $61.8 million at the end of 2020, with a net loss of $6.3 million for the quarter.

Vincerx Pharma, Inc. (Nasdaq: VINC) announced the completion of its redemption event for outstanding public warrants on May 5, 2021. Approximately 99% of the 6,563,767 Public Warrants were exercised, generating $37.3 million in cash proceeds. The redemption price was set at $0.01 per warrant. A total of 17,505,239 shares of common stock were outstanding following the event. This move strengthens Vincerx's financial position as it focuses on advancing new cancer therapies through its pipeline, which includes an exclusive agreement with Bayer.

Vincerx Pharma announced FDA clearance for its Investigational New Drug application to initiate a Phase 1b dose escalation study of VIP152, a selective CDK9 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). This marks Vincerx's first IND clearance and second clinical program. The trial aims to enroll patients who failed prior treatments, with the study initiating in 2H 2021. Additionally, Vincerx is progressing in its first-in-human study for advanced cancers, set to begin patient dosing in Q2 2021.

Vincerx Pharma presented promising preclinical data for VIP236, a novel small molecule drug conjugate, at the AACR Annual Meeting 2021. This drug targets the αvβ3 integrin linked to a cytotoxic camptothecin derivative, showcasing enhanced tumor targeting and significant anti-tumor activity across various xenograft models. Specifically, complete tumor regression was observed in 100% of cases in a triple-negative breast cancer model. With first-in-human studies expected in the first half of 2022, VIP236 may address critical needs in aggressive cancer treatment.

PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma (Nasdaq: VINC) will host a key opinion leader (KOL) meeting on bioconjugation and CDK9 inhibitors on April 16, 2021, at 12:00 PM ET. KOLs Brian Druker, M.D., and Anthony W. Tolcher, M.D., will present and answer questions regarding advancements in cancer treatments. Vincerx will also discuss its novel small molecule drug conjugate targeting multiple cancers and its bioconjugation platform, which includes several promising candidates for hematologic tumors.

Vincerx Pharma announced the redemption of all outstanding public warrants to purchase its common stock, effective May 5, 2021. The redemption price is set at $0.01 per warrant. These warrants can be exercised until the redemption date, where unexercised warrants will become void. The company has met the criteria for redemption, as its stock price has consistently exceeded $16.50 for 20 trading days within the past 30 days. A total of 6,563,767 public warrants were issued, potentially raising approximately $37.7 million if fully exercised.

Vincerx Pharma, a biopharmaceutical firm focused on cancer therapeutics, has established a Scientific Advisory Board (SAB) led by John C. Byrd, M.D. The board includes renowned experts in oncology, enhancing Vincerx's capacity to advance its oncology pipeline. CEO Ahmed Hamdy emphasized that the SAB's expertise is pivotal for the development of VIP152, a CDK9 inhibitor targeting hematologic malignancies and solid tumors. The company's strategic direction is strengthened with the formation of this board, aimed at addressing unmet medical needs in cancer treatment.

Vincerx Pharma, Inc. (Nasdaq: VINC) made significant strides with an exclusive license agreement with Bayer AG for its oncology portfolio, including the promising CDK9 inhibitor VIP152. The company raised about $62 million through a successful business combination on December 23, 2020. Leadership was strengthened with new appointments, enhancing strategic direction. Phase 1b studies for VIP152 will begin in 2021, targeting Myc-driven hematologic malignancies. Financially, Vincerx ended Q4 2020 with $61.8 million in cash, though it reported a net loss of $10.7 million for the year.

PALO ALTO, Calif., March 10, 2021 - Vincerx Pharma (Nasdaq: VINC) announced a poster presentation at the AACR Annual Meeting 2021, scheduled for April 10-15, 2021. The poster titled 'A novel small molecule drug conjugate' focuses on a new drug designed to treat multiple cancer types. The presentation will be led by Hans-Georg Lerchen as part of the Experimental and Molecular Therapeutics session. Vincerx, a clinical-stage life sciences company, aims to address unmet medical needs in oncology through innovative therapies.